249 related articles for article (PubMed ID: 18271006)
1. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
2. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
3. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
5. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.
Viti F; Tarli L; Giovannoni L; Zardi L; Neri D
Cancer Res; 1999 Jan; 59(2):347-52. PubMed ID: 9927045
[TBL] [Abstract][Full Text] [Related]
6. Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.
Bootz F; Schmid AS; Neri D
Inflamm Bowel Dis; 2015 Aug; 21(8):1908-17. PubMed ID: 25993691
[TBL] [Abstract][Full Text] [Related]
7. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
Hemmerle T; Neri D
Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
[TBL] [Abstract][Full Text] [Related]
8. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
9. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.
Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D
Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
11. Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin.
Franz M; Hilger I; Grün K; Kossatz S; Richter P; Petersen I; Jung C; Gummert J; Figulla HR; Kosmehl H; Neri D; Berndt A; Renner A
J Heart Lung Transplant; 2013 Jun; 32(6):641-50. PubMed ID: 23701854
[TBL] [Abstract][Full Text] [Related]
12. A high-affinity human antibody that targets tumoral blood vessels.
Tarli L; Balza E; Viti F; Borsi L; Castellani P; Berndorff D; Dinkelborg L; Neri D; Zardi L
Blood; 1999 Jul; 94(1):192-8. PubMed ID: 10381513
[TBL] [Abstract][Full Text] [Related]
13. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases.
Rybak JN; Roesli C; Kaspar M; Villa A; Neri D
Cancer Res; 2007 Nov; 67(22):10948-57. PubMed ID: 18006840
[TBL] [Abstract][Full Text] [Related]
14. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.
Borsi L; Balza E; Bestagno M; Castellani P; Carnemolla B; Biro A; Leprini A; Sepulveda J; Burrone O; Neri D; Zardi L
Int J Cancer; 2002 Nov; 102(1):75-85. PubMed ID: 12353237
[TBL] [Abstract][Full Text] [Related]
15. A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.
Hemmerle T; Wulhfard S; Neri D
Protein Eng Des Sel; 2012 Dec; 25(12):851-4. PubMed ID: 22972762
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
17. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.
Berndorff D; Borkowski S; Moosmayer D; Viti F; Müller-Tiemann B; Sieger S; Friebe M; Hilger CS; Zardi L; Neri D; Dinkelborg LM
J Nucl Med; 2006 Oct; 47(10):1707-16. PubMed ID: 17015908
[TBL] [Abstract][Full Text] [Related]
18. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.
Ziffels B; Grötsch A; Al-Bayati L; Neri D
J Biotechnol; 2019 Jan; 290():53-58. PubMed ID: 30579890
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes.
Marty C; Odermatt B; Schott H; Neri D; Ballmer-Hofer K; Klemenz R; Schwendener RA
Br J Cancer; 2002 Jul; 87(1):106-12. PubMed ID: 12085265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
